Trung Huynh
Stock Analyst at UBS
(3.79)
# 792
Out of 4,479 analysts
26
Total ratings
70%
Success rate
29.46%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $46 → $58 | $64.50 | -10.08% | 2 | May 29, 2024 | |
| BMY Bristol-Myers Squibb Company | Assumes: Neutral | $70 → $60 | $40.45 | +48.33% | 3 | Oct 20, 2023 | |
| LLY Eli Lilly | Assumes: Buy | $612 → $710 | $906.71 | -21.69% | 7 | Oct 20, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $170 → $175 | $146.03 | +19.84% | 2 | Jul 21, 2023 | |
| AMGN Amgen | Maintains: Outperform | $220 → $200 | $310.77 | -35.64% | 3 | Jul 12, 2023 | |
| PFE Pfizer | Downgrades: Neutral | $47 → $40 | $27.83 | +43.73% | 4 | Jun 29, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $125 → $126 | $127.72 | -1.35% | 3 | Mar 7, 2023 | |
| ABBV AbbVie | Initiates: Outperform | $170 | $165.96 | +2.43% | 1 | Nov 18, 2022 | |
| GRFS Grifols | Upgrades: Outperform | n/a | $6.52 | - | 1 | Mar 23, 2021 |
Insmed
May 29, 2024
Maintains: Buy
Price Target: $46 → $58
Current: $64.50
Upside: -10.08%
Bristol-Myers Squibb Company
Oct 20, 2023
Assumes: Neutral
Price Target: $70 → $60
Current: $40.45
Upside: +48.33%
Eli Lilly
Oct 20, 2023
Assumes: Buy
Price Target: $612 → $710
Current: $906.71
Upside: -21.69%
Johnson & Johnson
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $146.03
Upside: +19.84%
Amgen
Jul 12, 2023
Maintains: Outperform
Price Target: $220 → $200
Current: $310.77
Upside: -35.64%
Pfizer
Jun 29, 2023
Downgrades: Neutral
Price Target: $47 → $40
Current: $27.83
Upside: +43.73%
Merck & Co.
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $127.72
Upside: -1.35%
AbbVie
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $165.96
Upside: +2.43%
Grifols
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $6.52
Upside: -